234 related articles for article (PubMed ID: 15291653)
1. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.
Lu ML; Lane HY; Lin SK; Chen KP; Chang WH
J Clin Psychiatry; 2004 Jun; 65(6):766-71. PubMed ID: 15291653
[TBL] [Abstract][Full Text] [Related]
2. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.
Lu ML; Chen TT; Kuo PH; Hsu CC; Chen CH
Schizophr Res; 2018 Mar; 193():126-133. PubMed ID: 28688742
[TBL] [Abstract][Full Text] [Related]
3. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
Lu ML; Lane HY; Chen KP; Jann MW; Su MH; Chang WH
J Clin Psychiatry; 2000 Aug; 61(8):594-9. PubMed ID: 10982203
[TBL] [Abstract][Full Text] [Related]
4. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight.
Hinze-Selch D; Deuschle M; Weber B; Heuser I; Pollmächer T
Psychopharmacology (Berl); 2000 Apr; 149(2):163-9. PubMed ID: 10805611
[TBL] [Abstract][Full Text] [Related]
5. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.
Szegedi A; Anghelescu I; Wiesner J; Schlegel S; Weigmann H; Härtter S; Hiemke C; Wetzel H
Pharmacopsychiatry; 1999 Jul; 32(4):148-53. PubMed ID: 10505485
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
Wetzel H; Anghelescu I; Szegedi A; Wiesner J; Weigmann H; Härter S; Hiemke C
J Clin Psychopharmacol; 1998 Feb; 18(1):2-9. PubMed ID: 9472836
[TBL] [Abstract][Full Text] [Related]
7. Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy.
Légaré N; Grégoire CA; De Benedictis L; Dumais A
Med Hypotheses; 2013 Jun; 80(6):689-91. PubMed ID: 23490199
[TBL] [Abstract][Full Text] [Related]
8. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
[TBL] [Abstract][Full Text] [Related]
9. [Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].
Papetti F; Morel-Pingault V; Buisse V; Maziere L; Banayan M; Thauby S; Besnard T; Darcourt G; Pringuey D
Encephale; 2007 Oct; 33(5):811-8. PubMed ID: 18357853
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.
Tan MSA; Honarparvar F; Falconer JR; Parekh HS; Pandey P; Siskind DJ
Psychopharmacology (Berl); 2021 Mar; 238(3):615-637. PubMed ID: 33410989
[TBL] [Abstract][Full Text] [Related]
11. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
Andrade C
J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
[No Abstract] [Full Text] [Related]
12. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Atmaca M; Kuloglu M; Tezcan E; Ustundag B
J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
[TBL] [Abstract][Full Text] [Related]
13.
Boyle K; Cornett S; Fijtman A; Hunt-Harrison T
J Child Adolesc Psychopharmacol; 2021 Sep; 31(7):514-515. PubMed ID: 34166111
[No Abstract] [Full Text] [Related]
14. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
15. High-Dose Fluvoxamine Augmentation to Clozapine in Treatment-Resistant Psychosis.
Leising J; Barr AM; Procyshyn RM; Ainsworth NJ; White RF; Honer W; Vila-Rodriguez F
J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):186-190. PubMed ID: 33587389
[TBL] [Abstract][Full Text] [Related]
16. [Serious drug interaction between clozapine-Leponex and fluvoxamine-Fevarin].
Olesen OV; Starup G; Linnet K
Ugeskr Laeger; 1996 Nov; 158(48):6931-2. PubMed ID: 8984760
[TBL] [Abstract][Full Text] [Related]
17. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Krakowski M; Czobor P; Citrome L
Schizophr Res; 2009 May; 110(1-3):95-102. PubMed ID: 19269139
[TBL] [Abstract][Full Text] [Related]
18. The effects of novel antipsychotics on glucose and lipid levels.
Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC
J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594
[TBL] [Abstract][Full Text] [Related]
19. The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review.
Polcwiartek C; Nielsen J
Psychopharmacology (Berl); 2016 Mar; 233(5):741-50. PubMed ID: 26626327
[TBL] [Abstract][Full Text] [Related]
20. The relationship between serum clozapine concentrations and hematological parameters by a validated mass spectrometric method.
Kamil Gharab KM; Onmaz DE; Abusoglu S; Aydin M; Sivrikaya A; Tok O; Abusoglu G; Unlu A
J Pharm Biomed Anal; 2020 Feb; 180():113056. PubMed ID: 31887669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
